Sign in Subscribe

Summit's Lung Cancer Drug: A Tale of Two Continents

Summit Therapeutics' promising lung cancer drug, ivonescimab, shows great results in China but struggles in Western trials, raising questions about its global future and impact on biotech.

Summit's Lung Cancer Drug: A Tale of Two Continents
Photo by National Cancer Institute on Unsplash

This post is for paying subscribers only

Already have an account? Sign in.